Eli Lilly: Tirzepatide Shows Promise In Treating Obstructive Sleep Apnea In Two Phase 3 Clinical Trials
Tirzepatide lead to a 63% mean reduction in restricted/obstructed breathing events per hour in patients with moderate to severe obstructive sleep apnea Tirzepatide lead to weight reduction and was well tolerated by study participants with mild adverse …